RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML)

Clinical trials for RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML) trials appear

Sign up with your email to follow new studies for RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Can a Two-Pronged pill outsmart stubborn leukemia?

Disease control Recruiting now

This early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The stud…

Matched conditions: RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML)

Phase: PHASE1 • Sponsor: Hangzhou Polymed Biopharmaceuticals, Inc. • Aim: Disease control

Last updated Jul 25, 2026 00:00 UTC

RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML)

Get alerted when new RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (RR-AML) trials appear

Can a Two-Pronged pill outsmart stubborn leukemia?